Site icon pharmaceutical daily

Atopic Dermatitis Global Market Report 2022: Lack of Therapeutic Options for Chronic Hand Eczema Presents Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Atopic Dermatitis Market Size, Share and Trends Analysis by Region, Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others), Route of Administration (Injectable, Oral, Topical) and Segment Forecast, 2022-2027” report has been added to ResearchAndMarkets.com’s offering.

The Global Atopic Dermatitis market size was valued at US$6.8 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 10.3% during 2022-2027. The Global Atopic Dermatitis market report provides an executive-level overview of the atopic dermatits market worldwide today, with detailed forecasts of key indicators up to 2027.

This market intelligence report offers a thorough, forward-looking analysis of the global atopic dermatitismarket, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.

The Atopic Dermatitis market size was valued at US$6.8 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 10.3% during the forecast period (2022-2027). The market is driven by the rising prevalence of atopic dermatitis, and the rising demand for bioligcs in treating AD.

Scope

Reasons to Buy

Key Topics Covered:

CHAPTER 01 Executive Summary

CHAPTER 02 Research Scope and Segmentation

CHAPTER 03 Technology Briefing

CHAPTER 04 Disease Management

CHAPTER 05 Competitive Assessment

CHAPTER 06 Unmet Needs and Opportunity Assessment

6.1 Overview

6.2 Lack of Therapeutic Options for Chronic Hand Eczema

6.3 Better Long-Term Disease Control and Management

6.4 More Tolerable Topical Treatment Options

6.5 Improved Patient Treatment Compliance

6.6 Increased Diversity in AD Clinical Trial Recruitment

CHAPTER 07 R&D Strategies

7.1.1 Rise of the Jak Inhibitors

7.1.2 Rise of Interleukin-Inhibiting Biologics

7.1.3 Targeting New Signaling Pathways/Novel Targets

7.2 Clinical Trials Design

7.2.1 Clinical Trial Design in AD

7.2.2 Clinical Trial Design in CHE

CHAPTER 08 Pipeline Assessment

8.1 Overview

8.2 Promising Drugs in Clinical Development

8.2.1 Mild to Moderate Agents

8.2.2 Moderate-to-Severe Agents

CHAPTER 09 Pipeline Valuation Analysis

9.1 Overview

9.2 Competitive Assessment

9.2.1 Systemic Agents

9.2.2 Topical Agents

CHAPTER 010 Current and Future Players

10.1 Overview

10.2 Deal-Making Trends

CHAPTER 011 Atopic Dermatitis Industry Trends Analysis

CHAPTER 012 Global Atopic Dermatitis Revenue Opportunity

12.1 Global Atopic Dermatitis Market

12.2 COVID-19 Impact

CHAPTER 013 Atopic Dermatitis Drug Class Outlook

13.1 Atopic Dermatitis – Drug Class Deep Dive

13.1.1 Corticosteroids

13.1.2 Calcineurin Inhibitors

13.1.3 Pde4 Inhibitors

13.1.4 Biologics

13.1.5 Other Drug Classes

CHAPTER 014 Atopic Dermatitis Route of Administration Outlook

14.1 Atopic Dermatitis – Route of Administration Deep Dive

14.1.1 Injectable

14.1.2 Oral

14.1.3 Topical

CHAPTER 015 Atopic Dermatitis Regional Outlook

15.1 Atopic Dermatitis – Regional Deep Dive

15.1.1 North America

15.1.2 Europe

15.1.3 Asia-Pacific

15.1.4 RoW

CHAPTER 016 Trends, Drivers, and Challenges

16.1 Atopic Dermatitis – Market Trends

16.1.1 Constant Competition to Launch New Drugs

16.2 Atopic Dermatitis – Market Drivers

16.2.1 Rising Prevalence of Atopic Dermatitis

16.2.2 the Rising Demand for Biologics in Atopic Dermatitis

16.3 Atopic Dermatitis – Market Challenges

16.3.1 Increase of Hypersensitive Reaction Leading to Product Recalls

16.3.2 High Treatment Cost, and Lack of Reimbursement Guidelines in Developing Countries.

CHAPTER 017 Global Atopic Dermatitis Competitive Landscape

CHAPTER 018 Appendix

18.1 Abbreviations

18.2 Methodology

18.3 Key Themes Impacting the Pharmaceutical Industry

18.4 About the Publisher

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/o1eq1c

Source: GlobalData

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version